Company intelligence / Profile preview

bioSyntagma

Tempe, Arizona, United States

Ownership: Private
Development stage: Other

Overview

bioSyntagma’s Molecular Fingerprint™ platform enables comprehensive, multi-omic and spatial profiling of tissue to inform personalized cancer treatment selection, biomarker discovery, and predictive analytics; the platform is used by clinicians, academic researchers, and drug developers and has partnered with Takara Bio USA on high-throughput SARS-CoV-2 detection

Therapeutic areas: Oncology
Modalities: Device (platform)Predictive analytics (enabling, not itself a therapeutic modality)Multi-omic profiling
Industry: Molecular Diagnostics

Partnerships

Takara Bio USA (COVID-19 detection method development and validation)Strategic partners and Big Pharma for biomarker discovery services (specific companies not named)

Beyond the preview

Go deeper on bioSyntagma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bioSyntagma.

Explore the full profile